Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Gastrointestinal Stromal Tumors

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Resectable Primary GISTs

Broader topic: Gastrointestinal Stromal Tumors

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
resectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Treatment of Resectable Primary GISTs

      Study evidence for this setting

      0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2008-12-19 · Gleevec (imatinib mesylate) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-gastrointestinal-stromal-tumors-scoped-c3726277
      event id
      fda-32f6e9c404cee22a
      event date
      2008-12-19
      event kind
      accelerated-approval
      drug or regimen
      Gleevec (imatinib mesylate)
      source indication text
      Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)
      match phrase
      gastrointestinal stromal tumors
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-4a42bbb412ec8119dff7
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2012-01-31 · Gleevec (imatinib mesylate) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-gastrointestinal-stromal-tumors-scoped-c3726277
      event id
      fda-2713a8fbbf981c0e
      event date
      2012-01-31
      event kind
      traditional-approval
      drug or regimen
      Gleevec (imatinib mesylate)
      source indication text
      Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)
      match phrase
      gastrointestinal stromal tumors
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-4a42bbb412ec8119dff7
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice